As gene therapy programs advance toward commercialization, manufacturing decisions made early can have a lasting impact on product quality, scalability, and regulatory success. In this virtual event, leading CDMOs share practical strategies for navigating process development, GMP manufacturing, tech transfer, and commercial readiness. Learn how the right development and manufacturing approach can reduce risk, streamline...
Once a fringe idea in chemical biology, targeted protein degradation (TPD) has become one of the most watched strategies in drug discovery. TPD has created new therapeutic opportunities for previously undruggable protein targets. Leading experts will discuss the design, challenges, and clinical promise of PROTACs in overcoming limitations of traditional small molecules. Ever wonder: How...
Discover how innovative media design strategies can help overcome productivity limitations in bioprocessing and drive higher titers without sacrificing product quality. In this webinar, experts will share a data-driven, bottom-up approach to media development using Design of Experiments (DOE) to identify the nutrients that have the greatest impact on cell culture performance. Learn how optimized...
Residual host cell DNA (residual DNA) is a critical quality attribute across biologics, vaccines and advanced therapy modalities, requiring sensitive and reproducible quantification to support process development, in-process control and lot release. However, traditional workflows can introduce variability and delay release timelines due to reliance on standard curves, multiple manual steps and method complexity. In...
The discussion will examine key manufacturing challenges and highlight where consumables add value, where they introduce unnecessary complexity, and how early upstream and downstream decisions impact long-term cost, scalability, and risk. Attendees will leave with key points to consider on how to approach consumables as a strategic part of manufacturing, rather than a line-item cost.
Rising regulatory expectations and increased scrutiny around particulate contamination are reshaping how risk is managed in bioprocessing. Particulate issues are often identified late in the process, leading to operational disruption, rework, and increased validation burden. This webinar explores how organizations can shift from reactive responses to proactive containment strategies. Using aggregated industry insights and representative...
What does it take to turn breakthrough biology into successful in vivo therapies? As innovations in synthetic biology, RNA editing, and gene therapy continue to accelerate, vector design and manufacturing remain the critical link between scientific discovery and patient impact. Join Chief Editor Erin Harris for a special Cell & Gene Live discussion with Robert...
In some ways, it has been a quiet(er) year on the regulatory front for mRNA; there have been no mRNA-specific guidances released since the MHRA personalized cancer immunotherapy guidance and the EMA’s mRNA vaccine quality guidance — both of which were released in the winter of 2025. However, there has been a flurry of activity...
As biologics, complex injectables, and stricter regulatory requirements reshape sterile manufacturing, facility design has become a critical factor in operational success. In this webinar, learn how purpose-built modular aseptic filling facilities can improve contamination control, manufacturing flexibility, and scalability compared with retrofitted legacy sites. Using real-world insights from Kindeva’s Bridgeton facility, attendees will explore how...
Join Good Days, MassBio, and leaders from across healthcare, biotechnology, patient advocacy, and public policy for a focused discussion on advancing innovation and improving access for people living with chronic and complex conditions. Observed annually on July 10 (7/10), Chronic Disease Day highlights a sobering reality: seven out of 10 deaths in the United States...
